Suven Pharmaceuticals Limited
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more
Suven Pharmaceuticals Limited (SUVENPHAR) - Total Assets
Latest total assets as of March 2025: ₹30.32 Billion INR
Based on the latest financial reports, Suven Pharmaceuticals Limited (SUVENPHAR) holds total assets worth ₹30.32 Billion INR as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Suven Pharmaceuticals Limited - Total Assets Trend (2019–2025)
This chart illustrates how Suven Pharmaceuticals Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Suven Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Suven Pharmaceuticals Limited's total assets of ₹30.32 Billion consist of 29.3% current assets and 70.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 2.8% |
| Accounts Receivable | ₹2.85 Billion | 9.4% |
| Inventory | ₹1.67 Billion | 5.5% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹638.90 Million | 2.1% |
| Goodwill | ₹6.55 Billion | 21.6% |
Asset Composition Trend (2019–2025)
This chart illustrates how Suven Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Suven Pharmaceuticals Limited's current assets represent 29.3% of total assets in 2025, a decrease from 49.8% in 2019.
- Cash Position: Cash and equivalents constituted 2.8% of total assets in 2025, up from 1.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 21.6% of total assets.
Suven Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Suven Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp Preferred
KO:000105
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma
KO:000220
|
Korea | ₩202.42 Billion |
|
Ildong Holdings Co Ltd
KO:000230
|
Korea | ₩813.62 Billion |
Suven Pharmaceuticals Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Suven Pharmaceuticals Limited generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Suven Pharmaceuticals Limited generates $8.73 in net profit.
Suven Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.43 | 11.82 | 1.95 |
| Quick Ratio | 1.98 | 9.65 | 1.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹5.23 Billion | ₹ 11.56 Billion | ₹ 1.91 Billion |
Suven Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Suven Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.25 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 34.5% |
| Total Assets | ₹30.32 Billion |
| Market Capitalization | $1.24 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Suven Pharmaceuticals Limited's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Suven Pharmaceuticals Limited's assets grew by 34.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Suven Pharmaceuticals Limited (2019–2025)
The table below shows the annual total assets of Suven Pharmaceuticals Limited from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹30.32 Billion | +34.50% |
| 2024-03-31 | ₹22.54 Billion | +14.67% |
| 2023-03-31 | ₹19.66 Billion | +7.44% |
| 2022-03-31 | ₹18.30 Billion | +24.08% |
| 2021-03-31 | ₹14.74 Billion | +25.72% |
| 2020-03-31 | ₹11.73 Billion | +49.78% |
| 2019-03-31 | ₹7.83 Billion | -- |